Beta Drugs Ltd

{
  "main_header": {
    "sid": 1002857,
    "name": "Beta Drugs Ltd",
    "stock_name": "Beta Drugs Ltd",
    "full_name": "Beta Drugs Ltd",
    "name_url": "stocks-analysis/beta-drugs",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,504.00",
    "chg": 130.3,
    "chgp": "5.49%",
    "dir": 1,
    "prev_price": "2,373.70",
    "mcapval": "2,811.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "BETA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE351Y01019",
    "curr_date": "Aug 10, 03:30 PM",
    "curr_time": "17:39 PM",
    "last_traded_at": "Aug 10, 03:30 PM IST",
    "bse_nse_vol": 65018,
    "exc_status": "Active",
    "traded_date": "Aug 10, 2026",
    "traded_date_str": "2026 08 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/beta-drugs-1002857-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Beta Drugs Ltd Technical Momentum Shifts Signal Mildly Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beta-drugs-ltd-technical-momentum-shifts-signal-mildly-bullish-outlook-4137112",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BetaDrugsLtd_technicaldot_4137112.png",
        "date": "2026-08-05 08:06:34",
        "description": "Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. This change accompanies impressive price returns that have outpaced the Sensex across multiple timeframes, signalling renewed investor interest and potential for sustained growth."
      },
      {
        "title": "Beta Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-hold-by-marketsmojo-4133660",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BetaDrugsLtd_mojoScore_4133660.png",
        "date": "2026-08-03 10:10:04",
        "description": "Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Beta Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-hold-by-marketsmojo-4117745",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BetaDrugsLtd_mojoScore_4117745.png",
        "date": "2026-07-23 10:10:04",
        "description": "Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 July 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Are Beta Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-beta-drugs-ltd-latest-results-good-or-bad-4114081",
        "imagepath": "",
        "date": "2026-07-21 19:15:43",
        "description": "Beta Drugs Ltd has reported its Q1 FY27 results, showcasing significant operational achievements that highlight its growth trajectory within the pharmaceutical sector. The company achieved net sales of ₹125.55 crores, reflecting a robust quarter-on-quarter growth of 33.62% and a year-on-year increase of 25.29%. This performance marks the highest quarterly revenue in the company's recent history, indicating strong demand and effective market positioning.\n\nThe operating margin for this quarter expanded to 21.80%, which is the highest recorded in recent quarters, demonstrating the company's ability to optimize its cost structure while maintaining pricing discipline. Additionally, net profit surged to ₹15.80 crores, representing a substantial quarter-on-quarter increase of 74.59% and a year-on-year growth of 35.04%. This indicates that the company is not only growing its revenue but is also effectively translat..."
      },
      {
        "title": "Are Beta Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-beta-drugs-ltd-latest-results-good-or-bad-4110079",
        "imagepath": "",
        "date": "2026-07-20 19:12:02",
        "description": "Beta Drugs Ltd's latest financial results present a complex picture characterized by both growth and operational challenges. In Q4 FY26, the company reported a net profit of ₹9.05 crores, reflecting a quarter-on-quarter increase of 6.22% and a year-on-year growth of 1.12%. This indicates that while the company is managing to grow its profits sequentially, the year-on-year growth is relatively modest, raising questions about its ability to leverage revenue expansion into significant profit gains.\n\nThe revenue for the same quarter reached ₹93.96 crores, marking a sequential growth of 7.67% and a year-on-year increase of 6.42%. This revenue growth is a positive sign; however, it is important to note that the operating margin, excluding other income, contracted to 18.82%, down from 19.47% in the previous quarter. This decline in operating margin suggests that the company is facing mounting cost pressures, which..."
      },
      {
        "title": "Beta Drugs Q1 FY27: Stellar 74.59% Profit Surge Defies Industry Headwinds",
        "link": "https://www.marketsmojo.com/news/result-analysis/beta-drugs-q1-fy27-stellar-7459-profit-surge-defies-industry-headwinds-4110793",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BetaDrugs_quaterlyResult_4110793.png",
        "date": "2026-07-20 18:31:50",
        "description": "Beta Drugs Ltd., the Himachal Pradesh-based pharmaceutical manufacturer, delivered a blockbuster first quarter for FY27, reporting consolidated net profit of ₹15.80 crores—a stunning 74.59% surge quarter-on-quarter and 35.04% growth year-on-year. The impressive performance triggered a sharp 9.43% rally in the stock, which closed at ₹2,439.40 on July 20, 2026, reflecting renewed investor confidence in the company's operational momentum."
      },
      {
        "title": "Beta Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-hold-by-marketsmojo-4097439",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BetaDrugsLtd_mojoScore_4097439.png",
        "date": "2026-07-12 10:10:03",
        "description": "Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Beta Drugs Ltd Falls 3.36%: 2 Key Technical Signals Shape Weekly Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beta-drugs-ltd-falls-336-2-key-technical-signals-shape-weekly-trend-4088632",
        "imagepath": "",
        "date": "2026-07-04 13:02:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>29 Jun:</strong> Week opens at Rs.2,163.10</p>\n                    <p><strong>30 Jun:</strong> Stock gains 1.00% despite Sensex dip</p>\n                    <p><strong>2 Jul:</strong> Golden Cross formation signals potential bullish breakout</p>\n                    <p><strong>3 Jul:</strong> Technical momentum shifts to bullish amid strong returns</p>\n                    <p><strong>3 Jul:</strong> Week closes at Rs.2,090.50 (-3.36%) underperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,163.10</div></div>\n                    <div class=\"..."
      },
      {
        "title": "Beta Drugs Ltd Technical Momentum Shifts to Bullish Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beta-drugs-ltd-technical-momentum-shifts-to-bullish-amid-strong-returns-4086964",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BetaDrugsLtd_technicaldot_4086964.png",
        "date": "2026-07-03 08:05:02",
        "description": "Beta Drugs Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend, supported by a confluence of positive technical indicators and robust price performance relative to the Sensex. This micro-cap pharmaceutical player’s recent technical signals suggest improving investor sentiment despite a minor day decline, positioning it as a stock to watch in the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 84,
    "sid": "1002857",
    "stock_news_url": "https://www.marketsmojo.com/news/beta-drugs-1002857"
  },
  "announcements": [
    {
      "details": "Beta Drugs Limited has informed the Exchange regarding 'International Plant Approvals'.",
      "source": "NSE",
      "caption": "Beta Drugs Limited - Updates",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "Beta Drugs Limitedgs Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Beta Drugs Limited - Reply to Clarification- Financial results",
      "datetime": "14-Nov-2019"
    },
    {
      "details": "Beta Drugs Limiteded for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Beta Drugs Limited - Clarification - Financial Results",
      "datetime": "08-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Beta Drugs Ltd has announced <strong>1:20</strong> bonus issue, ex-date: 26 Mar 25",
          "dt": "2025-03-26",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Beta Drugs Ltd Technical Momentum Shifts Signal Mildly Bullish Outlook

2026-08-05 08:06:34

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. This change accompanies impressive price returns that have outpaced the Sensex across multiple timeframes, signalling renewed investor interest and potential for sustained growth.

Read full news article

Beta Drugs Ltd is Rated Hold by MarketsMOJO

2026-08-03 10:10:04

Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Beta Drugs Ltd is Rated Hold by MarketsMOJO

2026-07-23 10:10:04

Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Are Beta Drugs Ltd latest results good or bad?

2026-07-21 19:15:43

Beta Drugs Ltd has reported its Q1 FY27 results, showcasing significant operational achievements that highlight its growth trajectory within the pharmaceutical sector. The company achieved net sales of ₹125.55 crores, reflecting a robust quarter-on-quarter growth of 33.62% and a year-on-year increase of 25.29%. This performance marks the highest quarterly revenue in the company's recent history, indicating strong demand and effective market positioning. The operating margin for this quarter expanded to 21.80%, which is the highest recorded in recent quarters, demonstrating the company's ability to optimize its cost structure while maintaining pricing discipline. Additionally, net profit surged to ₹15.80 crores, representing a substantial quarter-on-quarter increase of 74.59% and a year-on-year growth of 35.04%. This indicates that the company is not only growing its revenue but is also effectively translat...

Read full news article

Are Beta Drugs Ltd latest results good or bad?

2026-07-20 19:12:02

Beta Drugs Ltd's latest financial results present a complex picture characterized by both growth and operational challenges. In Q4 FY26, the company reported a net profit of ₹9.05 crores, reflecting a quarter-on-quarter increase of 6.22% and a year-on-year growth of 1.12%. This indicates that while the company is managing to grow its profits sequentially, the year-on-year growth is relatively modest, raising questions about its ability to leverage revenue expansion into significant profit gains. The revenue for the same quarter reached ₹93.96 crores, marking a sequential growth of 7.67% and a year-on-year increase of 6.42%. This revenue growth is a positive sign; however, it is important to note that the operating margin, excluding other income, contracted to 18.82%, down from 19.47% in the previous quarter. This decline in operating margin suggests that the company is facing mounting cost pressures, which...

Read full news article

Beta Drugs Q1 FY27: Stellar 74.59% Profit Surge Defies Industry Headwinds

2026-07-20 18:31:50

Beta Drugs Ltd., the Himachal Pradesh-based pharmaceutical manufacturer, delivered a blockbuster first quarter for FY27, reporting consolidated net profit of ₹15.80 crores—a stunning 74.59% surge quarter-on-quarter and 35.04% growth year-on-year. The impressive performance triggered a sharp 9.43% rally in the stock, which closed at ₹2,439.40 on July 20, 2026, reflecting renewed investor confidence in the company's operational momentum.

Read full news article

Beta Drugs Ltd is Rated Hold by MarketsMOJO

2026-07-12 10:10:03

Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Beta Drugs Ltd Falls 3.36%: 2 Key Technical Signals Shape Weekly Trend

2026-07-04 13:02:22

Key Events This Week

29 Jun: Week opens at Rs.2,163.10

30 Jun: Stock gains 1.00% despite Sensex dip

2 Jul: Golden Cross formation signals potential bullish breakout

3 Jul: Technical momentum shifts to bullish amid strong returns

3 Jul: Week closes at Rs.2,090.50 (-3.36%) underperforming Sensex

Week Open

Rs.2,163.10

Read full news article

Beta Drugs Ltd Technical Momentum Shifts to Bullish Amid Strong Returns

2026-07-03 08:05:02

Beta Drugs Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend, supported by a confluence of positive technical indicators and robust price performance relative to the Sensex. This micro-cap pharmaceutical player’s recent technical signals suggest improving investor sentiment despite a minor day decline, positioning it as a stock to watch in the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News